With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:
According to a note out of Bell Potter, its analysts have retained their buy rating on this location technology company's shares with an improved price target of $28.00. This follows the release of the company's full year results, which revealed revenue and EBITDA ahead of what both the broker and the market were expecting. In response, Bell Potter has upgraded its revenue forecasts in 2025 and 2026 by 3% and 4%. It has also upgraded its adjusted EBITDA forecasts by 21% and 20% and now forecast s2025 adjusted EBITDA of US$70 million. This is close to the middle of the guidance range provided by management. The Life360 share price is trading at $23.42 on Monday.
A note out of Morgans reveals that its analysts have retained their add rating on this gaming technology company's shares with an improved price target of $220.00. Morgans was impressed with the company's FY 2024 results and particularly the performance of the land-based segment, which delivered strong international sales and a net addition of 853 units in North America. Morgans boosting its earnings estimates for FY 2025 and FY 2026, partly due to the acquisition of Grover Gaming. This is expected to be supported by resilient demand in the United States and strong cost management. The Light & Wonder share price is fetching $179.40 today.
Analysts at Goldman Sachs have put a conviction buy rating on this sleep disorder treatment company's shares with an improved price target of $49.00. The broker highlights that ResMed is the world's leading CPAP manufacturer of devices and masks for the treatment of obstructive sleep apnoea (OSA). This is a great spot to be given robust CPAP patient growth, which is being assisted by a growing awareness of OSA. In addition, the broker believes that ResMed is well-placed for further market share gains, building on its number one global market position. Combined with operating margin expansion, Goldman forecasts ~10/15% CAGR for FY24-FY27 group revenue and net income, respectively. The ResMed share price is trading at $37.41 on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.